Dustri Online Services

Books: 0	Journals: 2	Articles: 4

Abstract

E.S. ELDesoky¹, V. Kumar², M.S. Alorainy³, M.M. Hamdi¹ and H. Derendorf²

¹Pharmacology Department, Faculty of Medicine, Assiut University, Assiut, Egypt, ²Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, USA, and ³Pharmacology Department, College of Pharmacy, Qasseem University, Saudi Arabia
Population pharmacokinetics (PK) of lithium as a mood stabilizer was investigated in Egyptian patients with bipolar affective disorders (n = 50) of whom 31 were suffering from lithium toxicity. The mean (± SD) age and body weight of patients were 33 ± 10 years and 67 ± 3.6 kg, respectively. Patients selected were maintained on lithium carbonate controlled release tablets at doses of 400 mg/12 hours (n = 43) or 200 mg/12 hours (n = 7) respectively. In 19 patients who continued lithium therapy, 1 blood sample/patient was withdrawn for lithium level determination before the morning dose of the drug was given while for 31 patients who suffered from lithium-related toxicity and cessation of drug intake was therapeutically decided, a single blood was drawn at variable time (36, 48 or 72 h) following the last administered dose of the drug. The data was subjected to population PK analysis using NONMEM and a two-compartment model was used. Due to single point sparse data, not all parameters and their between subject variability (BSV) could be determined. Therefore, lithium clearance (CL) and BSV were estimated while other PK parameters were fixed using available literature information. First order (FO) estimation method was used in the analysis. Covariates were evaluated by univariate analysis using likelihood ratio test. The most significant covariate on lithium CL was found to be creatinine clearance (CrCL). The population CL of lithium in the final model was expressed as CL_pop = 0.51 × (CrCL/105.3)^0.44. The final population PK parameters estimates of lithium were: CL = 0.51 l/h with 12.7% BSV, V₁ (Fixed) = 15.2 l, Q (Fixed) = 7.44 l/h, and V₂ (Fixed) = 6.7 l. The mean value of lithium concentration at 12 hours as predicted by the final model in the patients with drug toxicity was 1.3 ± 0.1 mmol/l versus 0.8 ± 0.14 mmol/l in patients without toxic signs. External validation of the final model on another group of adult bipolar patients (n = 12) maintained on lithium therapy showed a predictive ability of –35 to 65% as represented by% error for the predictions.Correspondence to:
Prof. Dr. E.S. ELDeskoy; Pharmacology Department, Faculty of Medicine, Assiut University, Assiut, Egypt
Email: [email protected]

Abstract

Nieren- und Hochdruckkrankheiten, Jahrgang 44, Nr. 11/2015, S. 481–482

NET-vermittelte extrazelluläre Histone verursachen bei schwerer Glomerulonephritis eine vaskuläre Nekrose

S.V. Kumar, O.P. Kulkarni, S.R. Mulay, M.N. Darisipudi, D. Thomasova, and H.-J. Anders

Nephrologisches Zentrum, Medizinische Klinik und Poliklinik IV, LMU München
Correspondence to:
Prof. Dr. med. Hans-Joachim Anders
Nephrologisches Zentrum
Medizinische Klinik und Poliklinik IV
Klinikum der Universität München, Campus Innenstadt
Ziemssenstraße 1
D–80336 München
Email: [email protected]

Abstract

Nieren- und Hochdruckkrankheiten, Jahrgang 44, Nr. 11/2015, S. 487

Von Podozyten stammendes CXCL12 spielt bei der glomerulären Schädigung und Regeneration eine Doppelrolle

S. Romoli, S.V. Kumar, S.R. Mulay, J. Desai, D. Thomasova, and H.-J. Anders

Nephrologisches Zentrum, Arbeitsgruppe Klinische Biochemie, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München
Correspondence to:
Prof. Dr. med. Hans-Joachim Anders
Nephrologisches Zentrum
Medizinische Klinik und Poliklinik IV
Klinikum der Universität München, Campus Innenstadt
Ziemssenstraße 1
D–80336 München
Email: [email protected]

Abstract

Nieren- und Hochdruckkrankheiten, Jahrgang 44, Nr. 11/2015, S. 491–492

Blockade von Cathepsin S – ein neuer Therapieansatz der Lupus-Nephritis

M. Tatò¹, S.V. Kumar¹, Y. Liu¹, S.R. Mulay¹, J. Eberhard¹, G. Hartmann² und H.-J. Anders¹

¹Nephrologisches Zentrum, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, ²Pharma Forschung und Entwicklung, Hoffman La Roche, Basel, Schweiz
Correspondence to:
Prof. Dr. med. Hans-Joachim Anders
Nephrologisches Zentrum
Medizinische Klinik und Poliklinik IV
Klinikum der Universität München, Campus Innenstadt
Ziemssenstraße 1
D–80336 München
Email: [email protected]

Shopping Overview
Type	Qtty	Discount	VAT	Price
Your basket is empty

View Cart

Search Results

Shopping Overview

Send us an E-Mail